You are on page 1of 4

17-B, Mahal Industrial Estate,

Mahakali Caves Road,


Andheri (E), Mumbai -400093. INDIA.
Tel. : (91-22) 6645 5645
Fax: (91-22) 6645 5685

ON No. L73100a1200SP1O10147
Wash* : unswariphermitin

SUN PHARMA
ADVANCED RESEARCH
COMPANY LTD.

2801 Octobe 016

SPARC/Sec/SE/2016-17/032

BSE Ltd,
Market Operations Dept.
P. J. Towers, Dalal Street,
Mumbai -400001.

National Stock Exchange of India Ltd,


Exchange Plaza, 5th Floor,
Plot No. C/1, G Block,
Bandra Kurla Complex,
Bandra (East), Mumbai 400 051.
Dear Sirs,
Sub: Outcome of Board Meeting

The Board of Directors of the Company at their meeting held today from 11:30 am to 01:45 pm
took the following decision:
i. Took on record and duly approved the Un-audited financial results of the Company for the
quarter and six months ended 30th June, 2016 which are enclosed herewith along with the
Limited Review Report of the Auditors thereon as Annexure I.
v
Approved the 'Statement of Deviation(s) & Variation(s)' in the use of proceeds from the
objects stated in the Offer documents of the recently concluded Rights issue of the Company,
which was already reviewed by the Audit Committee in its meeting held earlier during the day.
A copy of the same is enclosed herewith as Annexure II.
iii. Annulled the forfeiture of 191 equity shares of the Company held by the following shareholder
on favorable consideration of the applications from him along with the amount which remained
unpaid on the aforesaid shares.
Name of the Shareholder

No. of shares on which forfeiture was annulled

Hitendrakumar Vallabhbhai Patel

Thanking you,
Yours faithfully,
For Sun harma Advanced Research Company Ltd

Debas
Company Secretary.
End: as above

Regd. Office : SPARC, Ako:a RoadfAkota, Baroda - 390 020.

191 shares

Sun Pharma Advanced Research Company Limited


Regd Office: Sun Pharma Advanced Research Centre,
Akota Road, Akota, Vadodara - 390 020. Tel. No.0265-2330815
CM No. : L73100012006PLC047837 Web Site: www.sunpharma.in

Statement of Unaudited Financial Results for the Quarter and Six Months ended September 30, 2016
Particulars

3 Months ended
30.09.2016
30.06.2016 30.09.2015
Unaudited
Unaudited
Unaudited

Income from Operations


Income from Operations
Total Income from Operations
Expenses
Cost of Materials Consumed
Employee Benefits Expense
Clinical Trials and Professional Charges
Depredation Expense
Other Expenses
.
Total Expenses
Profit ! (Loss) from Operations before Other income and Finance Costs
Other Income
Profit! (Loss) from ordinary activities before Finance Costs
Finance Costs
Profit / (Loss) from ordinary activities before Tax
Tax Expense
Net Profit! (Loss) for the period / year
Paid-up Equity Share Capital - Face Value? 1 each
Reserves excluding Revaluation Reserve
Earnings Per Share of! 1 each - in 2 (Basic and Diluted)
Not Annualised
.
See accompanying Notes to the financial results

T In Lakhs
Year ended
. 31.03.2016
Audited

6 Months ended
30.09.2016
30.09.2015
Unaudited
Unaudited

9,489
9,489

2148
2,148

4,312
4,312

11,637
11,637

8,656
8,656

16,128
16,128

927
2,241
3,960
211
1,037
8,376
1,113
404
1,517
43
1,474

422
2,037
2,314
196
966
5,955
(3,807)
299
(3,508)
133
(3,641)

624
1,362
2,747
189
1,169
8,091
(1,779)
21
(1,768)
16
(1,774)

1,349
4,278
6,274
407
2,023
14,331
(2,694)
, 703
(1,991)
176
(2,167)

920
2,727
4,902
371
1,696
10,818
(1,060)
42
(1,918)
21
(1,939)

1,887
5,660
11,954
758
2,946
23,205
(7,077)
294
(6,783)
216
(6,999)

'
1,474
2,469

(3,641)
2,469

(1,774)
2,367

(2,167)
2,469

(1,939)
2,367

OLT

(1.47)*

(0.75)*

(0.813)*

(0.82)*

(6,999)
2,367
623
(2.96)

T in La khs
Mat
31.03.2016
Audited

"
Mat
30.09.2016
Unaudited

Particulars

A EQUITY AND LIABILMES


I Shareholders Funds
(a) Share Capital
(b) Reserves and Surplus
Sub-total- Shareholders' Fund.
II Share Application Money Pending Allotment
III Amount received on application for Annulment of Forfeiture of Shares
a T 7,777/1v Non-current Liabilities
Long-term Borrowings
(a)
Deferred Tax Liabilities (Net)
(b)
(c)
Long-term Provisions
Sub-total - Noncurrent Liabilities
v Current Liabilities
(a) Short-term Borrowings
(b) Trade Payables
(c) Other Current Liabilities
(d) Short-term Provisions
Sub-total -Current Liabilities

i
4

TOTAL EQUITY AND LIABILITIES


B ASSETS
I Non-current Assets
Fixed Assets
(a)
Long-term Loans and Advances
(b)
Other Noncurrent Assets
(d)
Sub-total - Noncurrent assets
II Current Assets
(a) Current Investments
(b) Trade Receivables
(c) Cash and Cash Equivalents
(d) Short-term Loans and Advances
Other Current Assets
(a)
Sub-total Current assets
TOTAL - ASSETS

2,489
23,366
25,825

2,367
623
2,990

190

05

218
329
547

273
_
329
602

6
7,700
1,394
364
9,463

5,248
5,815
1,209
212
12,484

,j,835

16 266

7,148
2,589
128
9,883

7,083
2,404
120
9,607

1
2,418
18,703
4,475
355
25,972

916
1,275
4,409
59
6,659

35,835

16,266

The above results are as per the Regulation 33 of the SEB1 (Listing Obligations and Disclosure Requirements) Regulations, 2015 and have been taken on record by the Board of Directors at its
meeting held on October 28, 2016 after being reviewed by the Audit Committee end have been subjected to a limited review by the Statutory Auditors of the Company.

The Company has only one reportable business segment namely 'Pharmaceutical Research 8 Development'.
During the quarter, the Company has annuled forfeiture of 4351, equity shares, pursuant to request received from the- concerned shareholders along with the unpaid call money with interest.
Previous periods (year figures have been regrouped (rearranged, wherever necessary, to correspond to current period's presentation.
order of the Board

3
4

mumbai, October 28, 2016

eitfr
For Identification
Deloitte Haskins & Sells LLP

Dilip S. Shanghvi
Chairman and Managing Director

Sun Pharma Advanced Research Company Limited


Regd Office. Sun Phartna-Adlianced Research Centre,
Akota Road, Akota, Vadodara - 390 020. Tel. No.0265-2330815
CIN No.: L73100012006PLC047837 Web Site: www.sunpharma. in

Status of Utilisation of rights issue proceeds for the Half year ended September 30, 2016

Particulars

Research and Development activities - clinical trials


General corporate purposes
Issue expenses
Total amount utilised

Amount of
funds
required as
per the Letter
of Offer

Amount
utilised till
30th
September
2016

? In Laths
19,474
5,272
253
25,000

r in Laths
2,471
4,434
153
7,058

r in Lakhs
Balance
unutilised
amount as on
30th
September
2016
Z in Laths
17,003
838

101
17,942

By order of the Board

01)

Mumbal, October 28, 2016

Dilip S. Shanghvi
Chairman and Managing Director